News & Analysis as of

Substance Abuse Opioid Coronavirus/COVID-19

McCarter & English, LLP

Federal Efforts to Address Opioid Use Disorder

On April 4, 2024, a final rule published on February 2, 2024 (the Final Rule) went into effect that concerns medication for the treatment of opioid use disorder. The Final Rule, published by the Substance Abuse and Mental...more

Goodwin

SAMHSA Final Rule Codifies Opioid Treatment Program Telehealth and Take-Home Medication Flexibilities

Goodwin on

On February 2, 2024, the Department of Health and Human Services (HHS) issued a Final Rule that expands access to medications for the treatment of opioid use disorder (OUD) via telehealth modalities and “take-home” doses....more

Foley & Lardner LLP

Opioid Treatment Programs: SAMHSA Makes Permanent Regulatory Flexibilities

Foley & Lardner LLP on

On February 1, 2024, the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services, announced a final rule updating the regulations regarding Opioid Treatment Programs...more

Harris Beach PLLC

HHS Office of Inspector General Publishes August Work Plan Updates

Harris Beach PLLC on

In its August 15, 2023, Enforcement listserv notice, the U. S. Department of Health and Human Services Office of Inspector General (“OIG”) published its Work Plan Updates for August. This article will highlight three of the...more

Foley & Lardner LLP

2023 Medicare Physician Fee Schedule Advances Access to Whole Person Treatment for Substance Use Disorders and Behavioral Health

Foley & Lardner LLP on

Starting January 1, 2023, Medicare will expand and increase coverage of certain services and providers to advance access to prevention and treatment services for substance use disorders (SUD) and mental health services. These...more

Foley & Lardner LLP

Telemedicine Laws for Opioids and Substance Use Disorder Treatment

Foley & Lardner LLP on

Continued access to telehealth services, particularly as it relates to medication assisted treatment (MAT) for substance use disorder (SUD), enjoys strong support among patients and clinicians, yet laws continue to trail...more

Maynard Nexsen

Taking the Pulse, A Health Care and Life Sciences Podcast | Episode 105: Sara Goldsby, Director, DAODAS

Maynard Nexsen on

On this episode of Taking the Pulse we welcome Sara Goldsby, Director of DAODAS. She answers questions about how the pandemic has impacted substance abuse disorders and their treatment, and offers insight into some of the...more

Patrick Malone & Associates P.C. | DC Injury...

Better Healthcare Newsletter from Patrick Malone - January 2022

If you’re already committed to a path to an Olympic gold medal or a marathon run, good for you! For the rest of us, there's this practical evidence-based advice for our New Year resolutions -- to feel better and fitter...more

Manatt, Phelps & Phillips, LLP

Telehealth and SUD: Lessons From the Pandemic

Editor’s Note: The COVID-19 pandemic drove significant expansion in state and federal telehealth policies, playing a critical role in ensuring access to substance use disorder (SUD) services, even during quarantine. ...more

Mintz - Health Care Viewpoints

Five Takeaways from DOJ’s Latest National Enforcement Action, Including Continued Focus on Opioids and Telemedicine

The U.S. Department of Justice (DOJ) recently announced its latest national enforcement action related to health care fraud (National Enforcement Action) in which DOJ filed criminal charges against 142 defendants. The...more

McGuireWoods Consulting

Washington Healthcare Update - July 2021 #1

This week in Washington: Senate in recess, conversations continue on infrastructure and administration’s health initiatives. ...more

Manatt, Phelps & Phillips, LLP

National Roadmap on State-Level Efforts to End the Drug Overdose Epidemic

Editor’s Note: The American Medical Association (AMA) and Manatt Health released a national roadmap in September 2019 to guide policymakers in taking action to help end the nation’s opioid epidemic. Based largely on in-depth...more

Foley & Lardner LLP

COVID-19 Compounds Opioid Crisis and Treatment Gaps for Vulnerable Americans: Will a Biden Administration and New Congress Expand...

Foley & Lardner LLP on

Payment misalignment in Medicare FFS for Substance Use Disorder (SUD) treatment as the subject of potential legislative and/or regulatory reforms - New opportunities for investor-backed behavioral health platforms in...more

Oberheiden P.C.

DEA Compliance for 2021 - How the DEA’s 2021 Proposed Aggregate Production Quotas Affect Pharmaceutical Companies and Society

Oberheiden P.C. on

The DEA struggles to balance the pressing need to provide pain relief for those suffering from the novel coronavirus with the ongoing effort to reduce the opioid epidemic in the United States. I. Overview on the DEA and the...more

Jackson Lewis P.C.

Study Finds Surge In Misuse Of Fentanyl, Heroin And Nonprescribed Opioids During COVID-19 Pandemic

Jackson Lewis P.C. on

According to a new Quest Diagnostics Health Trends study published on October 8, 2020, the misuse of fentanyl, heroin and nonprescribed opioids has increased during the COVID-19 pandemic. The study analyzed more than...more

ArentFox Schiff

Investigations Newsletter: DOJ Announces Charges Against 345 Defendants in Historic Nationwide Health Care Fraud and Opioid...

ArentFox Schiff on

DOJ Announces Charges Against 345 Defendants in Historic Nationwide Health Care Fraud and Opioid Takedown - The DOJ announced a nationwide enforcement action charging 345 defendants across 51 federal districts with...more

Bradley Arant Boult Cummings LLP

Opioid Guidance, Lactation Breaks, and Liability Shields: Recent Employment News You Might Have Missed

In case you missed it, below are a few of the most recent employment law updates that may have gotten lost in the onslaught of the 24-hour news cycle. EEOC Issues Opioid Accommodation Guidance - While employers have...more

Foley & Lardner LLP

Telehealth and Substance Use Disorder Treatment: Regulatory Barriers to Entry Can Mean Opportunity for Innovative Companies

Foley & Lardner LLP on

...As COVID-19 cases spread across the U.S., another public health issue continues to escalate: the rise of opioid-related overdose deaths. For patients with a substance use disorder (SUD), the pandemic has increased feelings...more

Baker Donelson

OIG to Audit Utilization of Medication-Assisted Treatment for Opioid Use Disorder

Baker Donelson on

The OIG has indicated concern that patients suffering from opioid use disorder may experience difficulty accessing medication-assisted treatment (MAT), resulting in under-utilization of this intervention that offers what the...more

Manatt, Phelps & Phillips, LLP

State Strategies to Support Access to SUD Treatment Services Through the COVID-19 Pandemic

Editor’s Note: Prior to the COVID-19 pandemic, many governors were looking for ways to strengthen substance use disorder (SUD) provider capacity as part of their comprehensive response to the opioid epidemic. With the...more

Fisher Phillips

The Opioid Crisis Meets The COVID-19 Pandemic: Employers Beware and Be Prepared

Fisher Phillips on

During the COVID-19 pandemic, employers have had to manage an ever-increasing variety of stressful employee related issues. However, as the crisis surges forward, with multiple states facing increased rates of infection as...more

McDermott Will & Emery

Exemptions and Considerations for the Treatment of Opioid Use Disorder During the COVID-19 Emergency

The Substance Abuse and Mental Health Services Administration (SAMHSA) has published new guidance for the care and treatment of substance use disorders during the COVID-19 outbreak. Of note, the guidance includes specific...more

22 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide